

1 **Chromatin accessibility landscapes activated by cell surface and intracellular immune**  
2 **receptors**

3

4 Pingtao Ding<sup>1,\*</sup>, Toshiyuki Sakai<sup>1</sup>, Ram Krishna Shrestha<sup>1</sup>, Nicolas Manosalva Perez<sup>2,3</sup>, Wenbin Guo<sup>4</sup>,  
5 Bruno Pok Man Ngou<sup>1</sup>, Shengbo He<sup>5</sup>, Chang Liu<sup>6</sup>, Xiaoqi Feng<sup>5</sup>, Runxuan Zhang<sup>4</sup>, Klaas  
6 Vandepoele<sup>2,3</sup>, Dan MacLean<sup>1</sup>, Jonathan DG Jones<sup>1,\*</sup>

7

8 1 The Sainsbury Laboratory, University of East Anglia, Norwich Research Park, Norwich NR4 7UH,  
9 United Kingdom

10 2 Department of Plant Biotechnology and Bioinformatics, Ghent University, Technologiepark 71,  
11 9052 Ghent, Belgium

12 3 VIB Center for Plant Systems Biology, Technologiepark 71, 9052 Ghent, Belgium

13 4 Information and Computational Sciences, The James Hutton Institute, Dundee DD2 5DA, United  
14 Kingdom

15 5 John Innes Centre, Norwich Research Park, Norwich NR4 7UH, United Kingdom

16 6 Institute of Biology, University of Hohenheim, Garbenstrasse 30, 70599 Stuttgart, Germany

17

18 \* For correspondence: [pingtao.ding@tsl.ac.uk](mailto:pingtao.ding@tsl.ac.uk) (lead contact); [jonathan.jones@tsl.ac.uk](mailto:jonathan.jones@tsl.ac.uk)

19

20 ORCID of authors:

21 PD: 0000-0002-3535-6053; TS: 0000-0003-2737-3299; RKS: 0000-0001-5542-6269; WG: 0000-  
22 0002-1829-6044; BN: 0000-0002-0760-1058; SH: 0000-0003-3773-9995; CL: 0000-0003-2859-4288;  
23 XF: 0000-0002-4008-1234; RZ: 0000-0001-7558-765X; KV: 0000-0003-4790-2725; DM: 0000-  
24 0003-1032-0887; JDGJ: 0000-0002-4953-261X

25

26 Twitter handles of first author and corresponding authors:

27 PD: [@sardineboy\\_DING](https://twitter.com/sardineboy_DING); JDGJ: [@jonathandgjones](https://twitter.com/jonathandgjones)

## 28 **Abstract**

29 Activation of cell Surface and Intracellular Receptor-Mediated Immunity (SRMI and IRMI) results in  
30 rapid transcriptional reprogramming that underpins disease resistance. However, the mechanisms by  
31 which SRMI and IRMI lead to transcriptional changes are not clear. Here, we combine RNA-seq and  
32 ATAC-seq to define changes in gene expression and chromatin accessibility; both SRMI and IRMI  
33 increase chromatin accessibility at induced defense genes. Analysis of ATAC-seq and RNA-seq data  
34 combined with publicly available information on transcription factor DNA-binding motifs enabled  
35 comparison of individual gene regulatory networks activated by SRMI and IRMI, and by both. These  
36 results and analyses reveal overlapping and conserved transcriptional regulatory mechanism between  
37 the two immune systems.

38

## 39 **Main**

40 Plants use both cell-surface and intracellular receptors to detect pathogen-derived molecules and  
41 activate innate immunity<sup>1</sup>. Plant cell-surface immune receptors (pathogen recognition receptors, or  
42 PRRs) perceive relatively conserved pathogen-associated molecular patterns (PAMPs) or endogenous  
43 damage-associated molecular patterns (DAMPs) released from damaged or dying plant cells and  
44 activate Pattern- or DAMP-triggered immunity (PTI or DTI)<sup>2,3</sup>. Intracellular immune receptors in  
45 plants are usually nucleotide-binding, leucine-rich repeat (NLR) proteins. NLRs recognize, directly or  
46 indirectly, pathogen effectors secreted into plant cells and activate effector-triggered immunity (ETI).  
47 These innate immune systems involve distinct responses mediated by different subsets of molecular  
48 components<sup>4</sup>. Some cell-surface receptors, such as tomato Cf-4 and Cf-9 detect apoplastic effectors  
49 yet activate PTI-like responses<sup>5</sup>. The fundamental distinction is between processes initiated by PRRs  
50 or NLRs, so we refer to surface-receptor-mediated immunity (SRMI, pronounced as ‘surmi’) and  
51 intracellular-receptor-mediated immunity (IRMI, pronounced ‘ermi’) instead of PTI and ETI  
52 (Supplementary Fig. 1). In interactions between plants and microbial pathogens, SRMI will always  
53 precede IRMI, since effector delivery requires close host/microbe interaction.

54

55 We study the Arabidopsis RPS4/RRS1 NLR pair that detects bacterial effectors AvrRps4 and PopP2.  
56 Using a *Pseudomonas* strain that solely delivers one of these effectors, we defined early RPS4/RRS1-  
57 dependent transcriptional responses in Arabidopsis leaves<sup>6,7</sup>, and showed that 4 hours after infiltration,  
58 SRMI together with IRMI ('SRMI+IRMI') elevates the expression of defense-related genes more  
59 strongly compared to SRMI alone<sup>6,8</sup>. This early timepoint precedes accumulation of defense hormone  
60 salicylic acid (SA) and gene reprogramming in response to increased endogenous SA level<sup>6,8</sup>. This  
61 implies that IRMI-enhanced transcriptional regulation plays an essential role in conferring robust  
62 immune responses against pathogens<sup>4</sup>, but how IRMI activates defense genes remains unclear. To  
63 study IRMI-specific physiological changes, we generated an inducible IRMI system<sup>9</sup>.

64

65 Activation of SRMI, IRMI and 'SRMI+IRMI' lead to rapid transcriptional reprogramming<sup>6,8,10</sup>. Many  
66 transcriptional regulatory components are involved in orchestrating effective immunity in plants<sup>11,12</sup>,  
67 notably transcription factors (TFs)<sup>13</sup>, transcription co-repressors<sup>14</sup>, the Mediator complex<sup>15</sup>, histone-  
68 modifying enzymes<sup>16</sup>, and histone remodellers<sup>17</sup>. Little is known of how changes in transcription rates  
69 at defense genes are initiated, maintained and regulated upon the activation of either class of plant  
70 immune receptor.

71

72 Open or accessible chromatin regions (ACRs) at promoters and enhancers are associated with active  
73 gene expression in eukaryotes<sup>18</sup>. Applications of assays for transposase-accessible chromatin  
74 following by sequencing (ATAC-seq) in plants have revealed species-, tissue- and cell-type-specific  
75 chromatin signatures<sup>19-23</sup> in recent studies, but chromatin accessibility changes associated with  
76 inducible responses, such as immune activation are less well characterized. We hypothesized that  
77 correlating immunity-specific transcriptomes with an atlas of open chromatin profiles could reveal  
78 novel *cis*-regulatory elements (CREs) and associated regulatory mechanisms. We therefore performed  
79 a set of comparative analyses with ATAC-seq and RNA-seq data generated during SRMI,  
80 'SRMI+IRMI' and IRMI. This study provides a direct link between changes in chromatin  
81 accessibility and associated gene expression and new insights into the dynamics of chromatin  
82 accessibility landscapes and gene regulatory networks during plant immune activation.

83

#### 84 **ATAC-seq in Arabidopsis reveals tissue-specific chromatin accessibility**

85 ATAC-seq was first used to capture open chromatin regions in human cell lines and rapidly adapted  
86 to other eukaryotic systems including plants<sup>19,24</sup>. To study the dynamic chromatin features during  
87 plant immune activation, we established a protocol to prepare fresh nuclei isolated from adult rosette  
88 leaves of *Arabidopsis thaliana* Columbia-0 (Col-0) ecotype using fluorescence-  
89 activated nuclei sorting (FANS) (Supplementary Fig. 2a). A similar approach was reported  
90 previously<sup>19</sup>. To generate FANS-ATAC-seq libraries from multiple samples that are (i) compatible  
91 with the Illumina next-generation sequencing (NGS) sequencing platforms and (ii) can be multiplexed  
92 we designed and synthesized barcoded primers with 9-nucleotide (nt) unique indices for dual index  
93 and paired-end sequencing (Supplementary Fig. 2b-d; Supplementary Table 1). In a trial run we used  
94 10k, 20k, 50k and 80k sorted nuclei as ATAC input with a fixed amount of ‘tagmentation’ reaction, to  
95 obtain an optimal ratio between the input nuclei (DNA) and Tn5 transposase (Supplementary Fig. 3a).  
96 Purified naked *Arabidopsis* genomic DNA was tagmented in three replicates and sequenced as  
97 controls for ATAC-seq normalization (Supplementary Fig. 2d). In this trial FANS-ATAC-seq run, we  
98 observed reproducible accessible chromatin features captured in two biological replicates with  
99 different levels of input (Supplementary Fig. 3b-e).

100

101 To test if this ATAC-seq method is sensitive enough to detect tissue-specific chromatin accessible  
102 features, we additionally performed FANS-ATAC-seq with sperm nuclei (SN) and vegetative nuclei  
103 (VN), the male germ unit derived from *Arabidopsis* pollen grain. We found that ACRs enriched at the  
104 *SYSTEMIC ACQUIRED RESISTANCE DEFICIENT 1 (SARD1)* defense gene locus are only observed  
105 in somatic but not germline cells (Supplementary Fig. 4a). *SARD1* encodes a TF involved in plant  
106 immunity<sup>13,25,26</sup>. We inspected another well-known *Resistance (R)*-gene cluster on *Arabidopsis*  
107 chromosome 4 which harbors a group of N-terminal Toll/interleukin-1 receptor/resistance protein  
108 (TIR) domain-containing NLRs. Similar to *SARD1*, promoters of *RECOGNITION OF*  
109 *PERONOSPORA PARASITICA 4 (RPP4)* or *CHILLING SENSITIVE 2 (CHS2)*, *SUPPRESSOR OF*  
110 *NPRI-1*, *CONSTITUTIVE 1 (SNCI)*, *SIDEKICK SNCI 1 (SIKIC2)* and *RESISTANCE TO*

111 *LEPTOSPHAERIA MACULANS 3 (RLM3)* show enriched ACRs in leaf nuclei ATAC-seq data  
112 compared to the other four NLRs in the same gene cluster, but not in SN or VN ATAC-seq data  
113 (Supplementary Fig. 4b). This is consistent with the observation that expression levels of *RPP4/CHS2*,  
114 *SNCI*, *SIKIC2* and *RLM3* in Arabidopsis adult leaves are much higher than the other four NLRs in the  
115 same gene cluster<sup>27</sup>. Expression of *RPP4/CHS2*, *SNCI*, *SIKIC2* and *RLM3* in Arabidopsis leaves  
116 contributes to resistance against multiple pathogens<sup>28–32</sup>. In addition, trimethylation of the 4<sup>th</sup> lysine of  
117 the histone H3 (H3K4me3s), histone marks that are often associated with actively transcribed genes,  
118 is enriched in *RPP4/CHS2* and *SNCI* promoters in Arabidopsis<sup>33</sup>, supporting our ATAC-seq results  
119 (Supplementary Fig. 4b). Overall, ACRs enriched in immunity-related genes are specific to somatic  
120 but not to germline cells.

121

## 122 **ATAC-seq to study Arabidopsis inducible innate immunity**

123 We applied the FANS-ATAC-seq method to study changes in chromatin accessibility associated with  
124 gene expression induced by innate immunity. In Arabidopsis Col-0, two paired NLR proteins  
125 RPS4/RRS1 and RPS4B/RRS1B serve as intracellular NLR receptors activating IRMI upon  
126 recognition of AvrRps4, an effector derived from *Pseudomonas (P.) syringae* pv. *pisi*, a causal agent  
127 of bacterial blight in pea (*Pisum sativum*)<sup>34</sup>. We use a non-pathogenic strain of *P. fluorescens* Pf0-1  
128 engineered with the type III secretion system (T3SS) from *P. syringae* ('Effector-to-Host Analyzer' or  
129 EtHAN) tool to deliver wild-type AvrRps4 (Pf0-1:AvrRps4<sup>WT</sup>) or its mutant (Pf0-1:AvrRps4<sup>mut</sup>) into  
130 Col-0 leaf cells<sup>35,36</sup>. AvrRps4<sup>mut</sup> (KRYY135-138AAAA) is unable to activate IRMI mediated by  
131 RPS4/RRS1 and RPS4B/RRS1B<sup>34</sup>. Infiltration of Pf0-1:AvrRps4<sup>mut</sup> activates SRMI, and Pf0-  
132 1:AvrRps4<sup>WT</sup> activates 'SRMI+IRMI' (Supplementary Fig. 5a), as in previous reports<sup>4,8</sup>. We took  
133 samples at 4 hours post-infiltration (hpi) for ATAC-seq to monitor early changes during immune  
134 activation (Supplementary Fig. 5a)<sup>6,8</sup>. We obtained similar genome-wide ATAC-seq peak coverage  
135 patterns with different treatments (Supplementary Fig. 5b).

136

137 ATAC-seq peaks in all biological replicates under different conditions were enriched within 2  
138 kilobases (kb) upstream of the transcription start site (TSS) and within 1 kb downstream of the

139 transcript termination site (TTS) (Fig. 1a,b). The distribution of ACRs relative to genomic features  
140 was highly similar between all ATAC-seq data sets (Supplementary Fig. 5c-f; Supplementary Table  
141 2). Over 77% of ACRs are mapped to the putative gene promoters (pACRs; within 2 kb upstream of a  
142 gene) (Supplementary Fig. 5c-f), consistent with previously reported ATAC-seq data sets<sup>19,37</sup>. ~8% of  
143 ACRs mapped to distal intergenic genome loci (dACRs) (Supplementary Fig. 5c-f), slightly higher  
144 than 5.9% reported recently<sup>23</sup>. In addition, compared to 16,296 ACRs observed in total using a similar  
145 FANS-ATAC-seq approach in a recent report<sup>23</sup>, we obtained a range of 24,901 to 27,285 total ACRs  
146 (Fig. 1c; Supplementary Table 3), also slightly more than the 23,288 total reported elsewhere  
147 applying ATAC-seq with INTACT (isolation of nuclei tagged in specific cell types) purified nuclei<sup>20</sup>.  
148 Comparing ACRs enriched in all conditions, we found 10,658 (~ 40% of total ACRs) are shared (Fig.  
149 1c). The remaining 60% unshared ACRs may point to specific regulatory signals under each condition.

150

151 Among those shared ACRs, pACRs enriched at house-keeping gene loci, such as the *UBQ10*  
152 (*POLYUBIQUITIN 10*), show similar patterns in all conditions (Fig. 1d), consistent with the presumed  
153 constitutive expression. pACRs enriched at *SNCI* and *SARDI* are similar to those observed in our trial  
154 run (Supplementary Fig. 4a,b) and the major peaks of pACRs at these two gene loci under different  
155 conditions are similar. We observe additional small pACRs at *SNCI* and increased ACRs at the  
156 3'UTR of *SARDI* upon SRMI and 'SRMI+IRMI' treatment (Fig. 1e,f). Those observations are  
157 positively correlated with previous reports that expression of *SARDI* and *SNCI* are upregulated by  
158 immune activation<sup>8,33</sup>.

159

### 160 **Positive correlation of increased ACRs and expression of defense genes during SRMI** 161 **and 'SRMI+IRMI'**

162 We reported that some defense genes are induced by both SRMI and 'SRMI+IRMI' by profiling  
163 expressions of selected genes<sup>8</sup>. In this study, we performed genome-wide RNA-seq to study genes  
164 induced by SRMI and 'SRMI+IRMI' more extensively (Supplementary Fig. 6a,b). There are 4665  
165 and 5004 upregulated genes during SRMI and 'SRMI+IRMI' compared to the 'No treatment' control,

166 respectively. Among these, 4494 genes are shared by SRMI and ‘SRMI+IRMI’ (Supplementary Fig.  
167 6c, Supplementary Tables 4). Similarly, there are 5433 downregulated genes shared by SRMI and  
168 ‘SRMI+IRMI’ (Supplementary Fig. 6c). This greatly expands the shared list of genes showing similar  
169 regulatory patterns between SRMI and ‘SRMI+IRMI’ compared to our previous report  
170 (Supplementary Fig. 6c,d; Supplementary Tables 5)<sup>8</sup>. Upregulated genes shared by SRMI and  
171 ‘SRMI+IRMI’ are mostly enriched in gene ontology as defense-related genes or genes in response to  
172 stress (Supplementary Fig. 6e,g), whereas downregulated genes shared by both immune activation  
173 conditions are enriched with respect to genes involved in photosynthesis (Supplementary Fig. 6f,h).  
174 These results indicate a transcriptional reprogramming from photosynthesis to defense activation in  
175 Arabidopsis leaves upon activation of both immune conditions. In addition, we identified 3005 genes  
176 that are more strongly induced by ‘SRMI+IRMI’ compared to SRMI alone, and they distribute in  
177 Clusters 5, 7 and 9 based on their co-expression pattern (Supplementary Fig. 6d, i-k).

178

179 We hypothesized that rapid elevation of gene expression would be correlated with increased  
180 chromatin accessibility at these gene loci during immune activation, as active transcription usually  
181 requires increased access of DNA-binding proteins such as TFs and transcriptional machineries<sup>38</sup>. To  
182 test this, we displayed ATAC-seq and corresponding RNA-seq data for well-known defense gene loci  
183 (Fig. 2). These were *ISOCHORISMATE SYNTHASE 1 (ICS1)*, *ENHANCED DISEASE*  
184 *SUSCEPTIBILITY 5 (EDS5)* and *AVRPPHB SUSCEPTIBLE 3 (PBS3)*, genes involved in SA  
185 biosynthesis<sup>39-42</sup>; and *AGD2-LIKE DEFENSE RESPONSE PROTEIN 1 (ALD1)*, *SAR DEFICIENT 4*  
186 *(SARD4)* and *FLAVIN-DEPENDENT MONOOXYGENASE 1 (FMO1)*, genes involved in synthesizing  
187 pipecolic acid (Pip) and its derivatives, that contribute to systemic acquired resistance (SAR) and  
188 defense priming<sup>43-46</sup>. We observed strongly increased ACRs at the promoters of all six selected genes  
189 in SRMI and ‘SRMI+IRMI’ compared to ‘No treatment’ or Mock treatments (Fig. 2a-f) and increased  
190 transcripts of those genes (Fig. 2g-i). This indicates a positive correlation between rapid  
191 transcriptional upregulation of selected defense genes and increased ACRs near the corresponding  
192 gene loci during activation of SRMI and ‘SRMI+IRMI’.

193

## 194 **Genome-wide assessment of gene regulatory changes during IRMI**

195 Activation of IRMI requires effector delivery from a pathogen, so will usually be preceded by SRMI  
196 (except perhaps for some recognized viruses). Previous studies on ETI (aka IRMI) usually involve  
197 effector delivery from *Pseudomonas sp.* or *Agrobacterium* transient expression, and thus are studies  
198 on ‘SRMI+IRMI’. We reported previously an inducible IRMI system by expressing AvrRps4<sup>WT</sup>  
199 (SETI<sup>WT</sup>) in which AvrRps4<sup>WT</sup> is only expressed upon  $\beta$ -estradiol (E2) induced nuclear binding of  
200 XVE to the LexA operon (E2:AvrRps4<sup>WT</sup>)<sup>9</sup>. This system enables investigation of IRMI-specific  
201 physiological changes<sup>4</sup>.

202

203 IRMI induced in SETI<sup>WT</sup> displays similar transcriptional dynamics to that induced by Pf0-1 EtHAN<sup>9</sup>.  
204 We focused on IRMI-specific transcriptional activation; all RNA-seq samples were collected at a  
205 relatively early time point of the activation (4 hpi of E2) (Supplementary Fig. 7a)<sup>4,9</sup>. To obtain the list  
206 of differentially expressed genes (DEGs) during IRMI, we compared gene expression profiles in E2-  
207 treated SETI<sup>WT</sup> at 4 hpi (IRMI) to those in E2-treated SETI<sup>WT</sup> at 0 hpi (Control\_1) or to those in E2-  
208 treated SETI<sup>mut</sup> at 4 hpi (IRMI\_mut) (Supplementary Fig. 7a-d; Supplementary Tables 6 and 7). The  
209 comparisons of ‘IRMI vs Control\_1’ and ‘IRMI vs IRMI\_mut’ share mostly the same genes in both  
210 up- and down-regulation groups (1584 shared upregulated and 1869 shared downregulated genes,  
211 respectively) (Supplementary Fig. 7b-d). The number of DEGs in ‘IRMI vs Control\_1’ is much more  
212 than that in ‘IRMI vs IRMI\_mut’ (Supplementary Fig. 7b,d). The majority of up- and down-regulated  
213 DEGs in ‘IRMI vs IRMI\_mut’ were shared by ‘IRMI vs Control\_1’ (Supplementary Fig. 7c;  
214 Supplementary Tables 6). From the gene ontology (GO) enrichment analysis of DEGs in those  
215 comparisons, we found the GO term of ‘response to wounding’ is enriched in DEGs of ‘IRMI vs  
216 Control\_1’ but not in that of ‘IRMI vs IRMI\_mut’ (Supplementary Fig. 7e-h). This indicates that both  
217 IRMI and IRMI\_mut activate genes that are induced by mechanical wounding via the infiltration  
218 process at 4 hpi. Thus, comparing IRMI to IRMI\_mut in ‘IRMI vs IRMI\_mut’ eliminates wounding-  
219 induced genes, and reduces background. From these DEGs in ‘IRMI vs IRMI\_mut’, we found genes  
220 mostly enriched in GO terms of ‘response to chitin’, ‘protein phosphorylation’ and ‘defense response’,  
221 (Supplementary Fig. 7i-k)<sup>4</sup>.



222

223 To study the changes in accessible chromatin on the loci of DEGs, we performed FANS-ATAC-seq  
224 (Supplementary Fig. 8a). Instead of using E2 treatment at 0 hpi, we use mock-treated sample at 4 hpi  
225 as a negative control, imitating the effects from wounding (Supplementary Fig. 8a). We observed  
226 consistent genomic distribution patterns of ACRs in all samples (Supplementary Fig. 8b-j;  
227 Supplementary Tables 8). To demonstrate ACRs that are specifically induced by IRMI compared to  
228 all control conditions, we checked the *ICSI* locus in comparison to the house-keeping gene *UBQ10*  
229 locus (Fig. 3a,b). We found only IRMI induces DARs at *ICSI* promoter and 3'UTR, but not in the  
230 'No treatment\_1' control (Fig. 3a). In contrast significant DARs are induced at *UBQ10* promoter and  
231 proximal region among all treatments (Fig. 3b). This is consistent with stable expression of *UBQ10*  
232 under all conditions.

233

#### 234 **Integration of ATAC-seq and mRNA-seq results in SRMI, IRMI and 'SRMI+IRMI'**

235 To identify genome-wide DARs that are activated by SRMI, IRMI and 'SRMI+IRMI' we normalized  
236 the ATAC peaks enriched in SRMI, IRMI and 'SRMI+IRMI' treatments compared to corresponding  
237 control conditions (Supplementary Fig. 9a-c). We found that DARs are upregulated at promoters of  
238 *ICSI* and *FMO1* as well as the NADPH oxidase encoding *RbohD* in response to the activation of  
239 SRMI, IRMI and 'SRMI+IRMI' (Fig. 4a), consistent with their upregulated gene expression in these  
240 conditions (Supplementary Fig. 6 and 7)<sup>4</sup>. We also found that no DARs are observed at *BIK1* locus  
241 under SRMI, IRMI and 'SRMI+IRMI' (Fig. 4b), though *BIK1* gene expression is induced in all these  
242 conditions (Supplementary Fig. 6 and 7)<sup>4</sup>. In addition, we observed that DARs at *PEP1 RECEPTOR 2*  
243 (*PEPR2*) and *SARD1* loci are only significantly induced by IRMI (Fig. 4b), but their gene expression  
244 is induced at all immune activation conditions (Supplementary Fig. 6 and 7)<sup>4</sup>. This indicates that not  
245 all increased DARs activated by different immune systems are positively associated with their  
246 upregulated gene expression.

247

248 To determine the extent to which activated open chromatin regions from the ATAC-seq analysis are  
249 correlated with induced gene expression in all immune conditions we integrated our ATAC-seq data

250 with corresponding mRNA-seq data. We found 1646 gene loci with increased ATAC peaks (DARs)  
251 as well as significantly upregulated gene expression (DEGs) in SRMI versus ‘No treatment’, and  
252 1722 such loci in ‘SRMI+IRMI’ versus ‘No treatment’ (Fig. 4c; Supplementary Tables 9). By  
253 comparing the intersection of the positively correlated gene loci (‘DAR  $\cap$  DEG’), we found  
254 substantial overlap (1413 gene loci) between these two conditions (Fig. 4c; Supplementary Tables 9).  
255 Comparing ‘IRMI vs Mock’, we found 947 loci showing positive correlation of increased DARs and  
256 upregulated DEGs (Fig. 4d; Supplementary Tables 9). The same GO terms are enriched in both 1413  
257 and 947 loci lists (Supplementary Fig. 9c,d; Supplementary Tables 9). Thus, a common set of genes is  
258 activated during SRMI, IRMI and ‘SRMI+IRMI’, and transcriptional activation might require  
259 chromatin in these gene loci to open up for active transcription events.

260

261 To better understand DEGs and DAGs that are induced by SRMI, IRMI and ‘SRMI+IRMI’, we  
262 individually compared upregulated DEGs, DAGs and ‘DAR $\cap$ DEG’ that are activated in these  
263 conditions compared to corresponding control conditions (Fig.4 e-g; Supplementary Tables 9). We  
264 found a large proportion of both upregulated genes and increased DAGs are shared by all three  
265 immune activation conditions (Fig. 4e,f; Supplementary Tables 9). We then compared SRMI, IRMI  
266 and ‘SRMI+IRMI’ upregulated DEGs and DARs (‘DAR $\cap$ DEG’), and identified 782 gene loci are  
267 shared by SRMI, IRMI and ‘SRMI+IRMI’ (Fig. 4g, Supplementary Tables 9). These responses shared  
268 by SRMI, IRMI and ‘SRMI+IRMI’ could reveal common transcriptional regulatory mechanism,  
269 where a common set of TFs might be required for controlling gene expression.

270

### 271 **Transcriptional gene regulatory networks of SRMI, IRMI and ‘SRMI+IRMI’**

272 Identification of ACRs can assist to determine locations of putative CREs, where transcriptional  
273 regulators, especially DNA-binding proteins such as TFs, might bind. To identify regulatory  
274 interactions between TF regulators and target genes, gene regulatory networks (GRNs) were  
275 delineated through the integration of RNA-Seq, ATAC-Seq and TF motif information<sup>47</sup>. GRNs at an  
276 early time point (4 hpi) upon activation of SRMI, IRMI and ‘SRMI+IRMI’ were constructed, based  
277 on motifs enriched for DAR in these conditions. TF binding site mapping data for 1,793 motifs,

278 corresponding to 916 Arabidopsis TFs were used to link specific regulators with putative target genes,  
279 based on the motif location in the DAR and the closest gene<sup>47</sup>. To narrow down the list of TFs, we  
280 selected those which showed increased gene expression ( $\log_2FC > 1$ ,  $q\text{-value} < 0.01$ , Supplementary  
281 Tables 10). We identified 115, 34 and 133 TFs as regulators in SRMI, IRMI and ‘SRMI+IRMI’,  
282 based on the significant enrichment of 210, 73 and 248 motifs in the corresponding DARs (Fig. 5a,  
283 Supplementary Tables 10). Comparing regulators between the different conditions reveals that 25  
284 regulators, of which 72% are WRKY TFs, are common to all 3 networks, while 82 regulators are  
285 shared between SRMI and ‘SRMI+IRMI’, corresponding predominantly with WRKY, bHLH and  
286 bZIP TFs (Fig. 5b). This result reveals a diversity of TF families is playing an important role in the  
287 transcriptional reprogramming of gene expression during the activation of plant immunity.

288

289 To assess the biological processes controlled by these different regulators, GO enrichment was  
290 performed on each set of target genes, per network and per TF. We found ‘response to chitin’,  
291 ‘response to bacterium’ and ‘response to hypoxia’ are the top three GO terms that are commonly  
292 enriched in SRMI, IRMI and ‘SRMI+IRMI’ (Fig. 5c, Supplementary Fig. 10, Supplementary Tables  
293 10). Whereas most WRKYs are activated during immune responses independently of whether the  
294 activation occurs through surface or intracellular receptors, WRKY65 and WRKY59 are specific to  
295 IRMI, and the targets of WRKY59 are enriched in ‘regulation of cell death’ (Fig. 6, Supplementary  
296 Fig. 10b). Some examples of TFs implicated by this analysis, some of which have been confirmed in  
297 controlling hormone-related processes, are: (1) response to JA and SA in SRMI: AtIDD5; (2)  
298 response to SA in SRMI: KAN2, WRKY33, WRKY45, TGA7, and JKD; (3) SA signaling in IRMI:  
299 AT5G01380; and (4) response to SA in ‘SRMI+IRMI’: KAN2, ANAC029, ANAC046, ABO3, TGA3  
300 and TGA7 (Supplementary Fig. 10). Response to ABA was only observed for 8 WRKY TFs in SRMI  
301 (WRKY7, 11, 15, 17, 22, 40, 45 and 75), which might be mostly associated with the wounding  
302 response. Stronger induction of IRMI in addition to SRMI might be more dominant to this ABA or  
303 wounding-associated transcriptional regulation. Two members of the CAMTA transcription factor  
304 family (CAMTA1 and CAMTA3) are exclusively enriched in IRMI and were previously  
305 characterized as repressors of SA-regulated genes. However, upon pathogen infection CAMTA-

306 mediated repression is alleviated and plant defense genes are expressed<sup>48-50</sup>. These results indicate  
307 that the function of these CAMTA transcription factors involved in immunity are mediated by  
308 intracellular receptors. For SRMI there is only one TF exclusive to this condition, CBF2, that  
309 regulates a SRMI-specific GO term, ‘toxin metabolic process’.

310

311 The clustering coefficient of a network is a measure of the tendency of the nodes to cluster together,  
312 which for GRNs indicates that for specific genes, the incoming regulatory TFs are also controlling  
313 each other, suggesting TF crosstalk. The clustering coefficient is significantly higher for SRMI and  
314 IRMI networks than for ‘SRMI+IRMI’ and the intersection of SRMI, IRMI and ‘SRMI+IRMI’  
315 ( $SRMI \cap IRMI \cap \text{‘SRMI+IRMI’}$ , or ‘Set D’) (Supplementary Fig. 11). The IRMI network stands out  
316 having 23 genes with a clustering coefficient of 0.5 or higher, which are controlled by a combination  
317 of WRKY TFs (WRKY6, 26, 31, 40, 47 and 70), CAMTA3, HSF2A and IDD1 (Supplementary Fig.  
318 12). Overall, the inferred networks revealed that both shared and unique regulators are involved in  
319 controlling gene expression, with an important role for WRKY TFs controlling the ‘response to  
320 bacteria’ as well as other TFs regulating other hormone-related biological processes. In addition, the  
321 tight control of specific target genes by multiple TFs, some also controlling each other, enables  
322 investigation into the hierarchy of TF signaling in different types of immunity activation.

323

## 324 **Discussion**

325 Our understanding of transcriptional regulation in eukaryotes has been greatly advanced by  
326 sequencing methods developed for chromatin biology<sup>51</sup>. Genome-wide chromatin accessibility data  
327 for different plant species have demonstrated interesting aspects of mechanisms involved in  
328 transcriptional regulation of diverse biological processes<sup>20-23,37,52</sup>, but rarely for plant immunity.  
329 Several TFs have been implicated in plant innate immunity<sup>11,53</sup>. How these TFs function in a  
330 regulatory network has remained poorly understood. Here we report chromatin accessibility  
331 landscapes that are activated by both cell-surface- and intracellular- immune receptor-mediated  
332 immunity (SRMI and IRMI). There are few studies of IRMI in the absence of SRMI, and we highlight

333 here the similarity and differences for changes in chromatin accessibility and associated gene  
334 expression between these two systems.

335

336 From the minimum GRNs we constructed here based on our ATAC-seq and RNA-seq results, we  
337 show that WRKY transcription factors are the predominant players in the GRNs regulating most  
338 genes that are activated during both SRMI and IRMI. However, due to incomplete public data, our  
339 GRNs here cannot reflect all regulatory possibilities. For instance, the DNA-binding motifs of some  
340 TFs are still not known<sup>54</sup>. In addition, we prioritized upregulated genes in our analysis, and negative  
341 regulation of some genes upon TF binding might also play an important role. These networks will be  
342 further improved when more data become available.

343

344 For upregulated DEGs that show increased DARs, the binding of TFs might be correlated with the  
345 chromatin opening. However, it is challenging to distinguish whether TF binding is cause or  
346 consequence of chromatin opening. Some TFs can serve as ‘pioneer’ TFs to initiate transcription by  
347 recruiting ‘non-pioneer’ TFs, other transcriptional regulators and the RNA polymerase II  
348 machinery<sup>51,55,56</sup>. Such ‘pioneer’ TFs may recruit components that can open the chromatin, such as  
349 histone remodelers<sup>51</sup>. However more genetic evidence is required to evaluate this hypothesis.

350

351 The chromatin accessibility landscapes and implied GRNs reported here provide a snapshot of events  
352 during the activation of different immune responses. Transcription, like many other processes, is a  
353 dynamic, so it is important to profile the changes in chromatin accessibilities and corresponding gene  
354 expressions over a time-course. With time-series ATAC-seq and RNA-seq data in future studies, we  
355 will be able to generate dynamic transcriptional regulatory networks that will provide more novel  
356 insights into transcriptional regulatory mechanisms required for immune activation and for the  
357 establishment of disease resistance.

358

359 **Methods**

360 **Plant materials and growth condition.** *Arabidopsis thaliana* Columbia-0 (Col-0) accession was  
361 used as wild type in this study. SETI<sup>WT</sup> and SETI<sup>mut</sup> transgenic plants used have been described  
362 previously<sup>9</sup>. Seeds were sown on compost and plants were grown at 21 °C with 10 hours under light  
363 and 14 hours in dark, and at 70% humidity. The light level is approximately 180-200 μmol with  
364 fluorescent tubes.

365

366 **Activation of SRMI and ‘SRMI+IRMI’.** *Pseudomonas fluorescens* engineered with a type III  
367 secretion system (Pf0-1 ‘EtHAn’ strains) expressing one of wild-type AvrRps4 or AvrRps4  
368 KRVY135-138AAAA mutant effectors were grown on selective KB plates for 24 h at 28 °C<sup>6,35</sup>.  
369 Bacteria were harvested from the plates, resuspended in infiltration buffer (10 mM MgCl<sub>2</sub>) and the  
370 concentration was adjusted to OD<sub>600</sub> = 0.2 (10<sup>8</sup> CFU•mL<sup>-1</sup>). The abaxial surfaces of 5-week-old  
371 Arabidopsis leaves were hand infiltrated with a 1-mL disposable needleless syringe (Slaughter Ltd, R  
372 & L, catalogue number: BS01T). Leaves infiltrated with 10 mM MgCl<sub>2</sub> serves as mock treatment.  
373 Leaves infiltrated with Pf0-1:AvrRps4<sup>WT</sup> activates ‘SRMI+IRMI’, and those infiltrated with Pf0-  
374 1:AvrRps4<sup>mut</sup> activates SRMI only<sup>4</sup>.

375

376 **Activation of IRMI.** 5-week-old Arabidopsis leaves of SETI<sup>WT</sup> (E2:AvrRps4<sup>WT</sup>) infiltrated with 50  
377 μM β-estradiol (E2, Sigma-Aldrich, catalogue number: E8875; dissolved in 100% dimethyl sulfoxide,  
378 also known as DMSO, Sigma-Aldrich, catalogue number: D8418) activates ‘IRMI’ only, as described  
379 previously<sup>9</sup>. 0.1% DMSO (same titrate as 50 mM E2 stock solution diluted in pure water and  
380 generating 50 μM E2 working solution) in pure water used as mock treatment for infiltration with a 1-  
381 mL needleless syringe. SETI<sup>mut</sup> (E2:AvrRps4<sup>mut</sup>) with similar treatments as in SETI<sup>WT</sup> serve as  
382 additional negative IRMI controls, as described previously<sup>9</sup>.

383

384 **RNA isolation and sequencing (RNA-seq).** Leaf samples from SRMI, ‘SRMI+IRMI’, IRMI  
385 were isolated as described previously<sup>8</sup>. Total RNA samples are sent by dry ice to BGI for mRNA  
386 isolation and library construction and sequenced on BGISEQ-500 sequencing platforms.

387

388 **RNA-seq raw data processing, alignment and quantification of expression and data**

389 **visualization.** Raw reads are trimmed into clean reads by BGI bioinformatic service into 50 bp. At

390 least 12 million single-end clean reads for each sample were provided by BGI for RNA-seq analysis.

391 All reads have passed FastQC before the following analyses (Simon Andrews; FastQC:

392 <https://www.bioinformatics.babraham.ac.uk/projects/fastqc/>). All clean reads are either mapped to

393 TAIR10 Arabidopsis genome/transcriptome via TopHat2 or to a comprehensive Reference Transcript

394 Dataset for Arabidopsis (AtRTD2) containing 82,190 non-redundant transcripts from 34,212 genes

395 via Kallisto (SRMI and 'SRMI+IRMI') or Salmon (IRMI) tools<sup>57-60</sup>. Detailed scripts and versions of

396 each software can be found via the GitHub link:

397 [https://github.com/TeamMacLean/fastqc\\_kallisto\\_analysis](https://github.com/TeamMacLean/fastqc_kallisto_analysis). Mapped reads were sorted with SAMtools

398 and visualized in Integrative Genomics Viewer (IGV) with TAIR10 reference genome<sup>57,61,62</sup>. The

399 estimated gene transcript counts were used for differential gene expression analysis, statistical

400 analysis and data through the 3D RNA-seq software<sup>63</sup>. For both datasets, the low expressed transcripts

401 were filtered if they did not meet the criteria  $\geq 3$  samples with  $\geq 1$  count per million reads (CPMs).

402 An expressed gene must have at least one expressed transcript. The batch effects between biological

403 replicates were removed to reduce artificial variance with RUVSeq method<sup>64</sup>. The expression data

404 was normalized across samples with TMM method<sup>65</sup>. The significance of expression changes in the

405 contrast groups 'SRMI vs no treatment' and 'SRMI+IRMI vs no treatment', and 'IRMI vs Control\_1'

406 and 'IRMI vs IRMI\_mut' were determined by the limma-voom method<sup>66,67</sup>. A gene was defined as

407 significant DEG if the BH adjusted p-value  $< 0.01$  and  $\log_2(\text{fold\_change}) \geq 1$ .

408

409 **FANS-ATAC-seq.** Leaf samples from SRMI, 'SRMI+IRMI', IRMI and control conditions were

410 collected at 4 hpi of treatment (same time points as RNA-seq samples) or without any treatment. 2

411 fully expanded leaves with treatment from each plant and 3 plants in total are collected as one sample

412 and one biological replicate. 6 leaves of one sample were chopped quickly in 1 mL 4°C-prechilled

413 phosphate-buffered saline (PBS) buffer (1×, pH 7.4) with a clean unused razor blade (Agar Scientific

414 Ltd, catalogue number: T586) into fine pieces (less than 1 min). The leaf lysis containing crude nuclei  
415 extract was transferred and filtered through a 30- $\mu$ m CellTrics<sup>®</sup> cell strainer (Sysmex, catalogue  
416 number: 04-0042-2316) into a 100 $\times$ 16-mm round-base test tube (Slaughter Ltd, R & L, catalogue  
417 number: 142AS) with 1-mL sterile tip by pipetting. The sharp end of the tip was cut off and shortened  
418 with 2-mm in length by a pair of sterile scissors to minimize the damage to the nuclei. All samples of  
419 leaf lysis were kept on ice immediately after the transfer. 1-mL CyStain PI Absolute P nuclei 4',6-  
420 diamidino-2-phenylindole (DAPI) staining buffer (Sysmex, catalogue number: 05-5022) was added  
421 into each nuclei extract. Nuclei extract with the staining buffer were gently mix and kept on ice.  
422 Stained nuclei extract were submitted to BD FACSMelody Cell Sorter with a green laser for  
423 fluorescence-assisted nuclei sorting (FANS) with a similar setting as described previously<sup>19</sup>. FANS-  
424 purified nuclei samples were collected in 1.5 DNA LoBind Eppendorf microcentrifuge tubes (Fisher  
425 Scientific, catalogue number: 10051232) and kept on ice. Nuclei pellets were collected as described  
426 previously by centrifugation at 1,000  $\times$  g and tagmented with Nextera DNA Library Prep Kit  
427 (Illumina, catalog number: FC-121-1030, now discontinued; replacement can be found as Illumina  
428 Tagment DNA TDE1 Enzyme and Buffer Kits, catalog numbers: 20034197 or 20034198)<sup>68</sup>. We used  
429 0.1  $\mu$ L TDE1 enzyme in a 5  $\mu$ l total reaction mix for each ATAC samples. The following PCR library  
430 construction and quality control steps were performed as recommended<sup>68</sup>. The only difference here  
431 was that we used dual index primers designed by ourselves for barcoding the libraries and  
432 multiplexing. Those primers have been validated in our previous experiments<sup>8</sup>, and the detailed  
433 sequence information can be found in Supplementary Table 1. Multiplexed ATAC-seq libraries were  
434 sequenced with multiple NextSeq 500/550 High Output Kits (75 Cycles) on an in-house NextSeq 550  
435 sequencer.

436

437 **ATAC-seq raw data processing and alignment.** Sequencing results were demultiplexed using  
438 bcl2fastq tool to generate adaptor-trimmed raw reads. Pair-end and 37 bp each end reads were tested  
439 with FastQC and Picard tools for quality control and testing PCR duplications. Raw reads were  
440 mapped to TAIR10 Arabidopsis reference genome with Bowtie2 and sorted with SAMtools<sup>61,69</sup>.  
441 Reads mapped to chloroplast and mitochondria were removed before the follow-up analyses. Detailed



442 scripts, software versions and QC outputs can be found in the GitHub link:  
443 [https://github.com/TeamMacLean/dingp\\_atacseq\\_for\\_publication](https://github.com/TeamMacLean/dingp_atacseq_for_publication).

444

445 **Identification of ACRs.** Identification of ACRs was done by callpeak function in MACS v.2.2.7<sup>70</sup>.

446 All replicates of samples under specific condition were used as input of treatment and genomic DNA

447 samples were used as input of control. For visualization of fold enrichment of mapped reads

448 compared control samples, FE.bdg files were generated by bdgcmp function in MACS. FE.bdg files

449 were visualized by IGV<sup>62</sup>. In the trial analysis of FANS-ATAC-seq, we counted mapped reads for

450 ACRs using coverage function in Bedtools v.2.28.0<sup>71</sup>. Then, we made correlation plots based on log<sub>2</sub>

451 read counts of each common ACR between replicates to find out the reproducibility for 10k, 20k, 50k,

452 and 80k samples using our R script, which is listed in our GitHub link:

453 [https://github.com/slt666666/Plant\\_Innate\\_Immunity\\_ATAC-seq](https://github.com/slt666666/Plant_Innate_Immunity_ATAC-seq).

454

455 **Profile of ACRs binding to TSS/TTS regions.** The heatmap of ACRs binding to TSS regions

456 and the distribution of ACRs binding to TSS and TTS regions were obtained by CHIPSeeker v.1.24.0

457 package within R<sup>72</sup>. The features of ACRs were annotated by CHIPSeeker package using the

458 annotatePeak function. In this part, promoters were defined as -2,000 to 1,000 bp from the TSS. The

459 Upset plot which showed ACRs shared on several conditions were generated by UpSetR package

460 based on the nearest genes from ACRs<sup>73</sup>.

461

462 **Identification of DARs.** Identification of DARs is achieved by applying callpeak function of

463 MACS. All replicates of samples under specific condition were used as input of treatment and all

464 replicates of samples under corresponding control conditions were used as input of control.

465 Annotation of genes with enriched DARs within 2 kb upstream of a gene is done by

466 annotatePeakInBatch function in ChIPpeakAnno package<sup>72</sup>. Annotation of genes with the other DARs

467 in distal intergenic genome loci is done by our Python script.

468

469 **Integration of DEGs and DARs.** The identification of common genes to annotated genes with  
470 enriched DARs and significantly upregulated ( $\log_2FC > 1$ ,  $q\text{-value} < 0.01$ ) genes is done by our  
471 Python script. The GO analysis for these common genes is conducted by g:Profiler<sup>74</sup>. All scripts used  
472 for the analyses of ACRs and integration of DEGs and DARs are available:  
473 [https://github.com/slt666666/Plant\\_Innate\\_Immunity\\_ATAC-seq](https://github.com/slt666666/Plant_Innate_Immunity_ATAC-seq).

474

475 **Motif-based inference of gene regulatory networks using ACRs.** The inference of GRNs  
476 was done using an ensemble motif mapping method described previously<sup>75</sup>, combining all the  
477 matches from Find Individual Motif Occurrences (FIMO) with the top 7000 matches from Cluster-  
478 Buster (CB)<sup>76,77</sup>. This mapping information was used to determine which motifs were significantly  
479 enriched in the ACRs derived from the ATAC-seq experiments for each condition (SRMI, IRMI and  
480 ‘SRMI+IRMI’). Per condition, for TFs showing differential expression the associated motifs were  
481 tested for enrichment in the ACRs and significant motifs were retained (adjusted  $p\text{-value} \leq 0.01$ ).  
482 Based on motif coordinates in ACRs, individual motif matches were assigned to the closest gene,  
483 establishing a link between the TFs that bind these motifs and putative target genes. The differential  
484 expression information was integrated to identify only the TFs and target genes that were  
485 differentially expressed for each condition. Finally, for each TF, the putative target genes set was  
486 analyzed for over-represented GO Biological Process terms (only using experimentally and curated  
487 annotations; hypergeometric distribution  $q\text{-value} < 0.001$ ).

488

## 489 **Data availability**

490 All raw reads in this study have been uploaded to the European Nucleotide Archive (ENA) as data  
491 repository and can be retrieved through accession number PRJEB34955 and PRJEB38924 for RNA-  
492 seq and PRJEB38923 for ATAC-seq. For data reproducibility, all scripts generated in this study,  
493 software versions can be found in related GitHub links indicated in the Methods section.

494

## 495 **References**

496

- 497 1. Jones, J. D. G. & Dangl, J. L. The plant immune system. *Nature* **444**, 323–329 (2006).
- 498 2. Choi, H. W. & Klessig, D. F. DAMPs, MAMPs, and NAMPs in plant innate immunity.
- 499 *BMC Plant Biol.* **16**, 232 (2016).
- 500 3. Bacete, L., Mérida, H., Miedes, E. & Molina, A. Plant cell wall-mediated immunity: cell
- 501 wall changes trigger disease resistance responses. *Plant J.* **93**, 614–636 (2018).
- 502 4. Ngou, B. P. M., Ahn, H.-K., Ding, P. & Jones, J. D. Mutual Potentiation of Plant
- 503 Immunity by Cell-surface and Intracellular Receptors. *BioRxiv* (2020).
- 504 doi:10.1101/2020.04.10.034173
- 505 5. Hammond-Kosack, K. E. & Jones, J. D. G. PLANT DISEASE RESISTANCE GENES.
- 506 *Annu. Rev. Plant Physiol. Plant Mol. Biol.* **48**, 575–607 (1997).
- 507 6. Sohn, K. H. *et al.* The nuclear immune receptor RPS4 is required for RRS1SLH1-
- 508 dependent constitutive defense activation in *Arabidopsis thaliana*. *PLoS Genet.* **10**,
- 509 e1004655 (2014).
- 510 7. Ding, P. *et al.* High-resolution Expression Profiling of Selected Gene Sets during Plant
- 511 Immune Activation. *BioRxiv* (2019). doi:10.1101/775973
- 512 8. Ding, P. *et al.* High-resolution expression profiling of selected gene sets during plant
- 513 immune activation. *Plant Biotechnol. J.* (2020). doi:10.1111/pbi.13327
- 514 9. Ngou, B. P. M. *et al.* Estradiol-inducible AvrRps4 expression reveals distinct properties
- 515 of TIR-NLR-mediated effector-triggered immunity. *J. Exp. Bot.* **71**, 2186–2197 (2020).
- 516 10. Hillmer, R. A. *et al.* The highly buffered *Arabidopsis* immune signaling network
- 517 conceals the functions of its components. *PLoS Genet.* **13**, e1006639 (2017).
- 518 11. Tsuda, K. & Somssich, I. E. Transcriptional networks in plant immunity. *New Phytol.*
- 519 **206**, 932–947 (2015).
- 520 12. Li, B., Meng, X., Shan, L. & He, P. Transcriptional Regulation of Pattern-Triggered
- 521 Immunity in Plants. *Cell Host Microbe* **19**, 641–650 (2016).
- 522 13. Zhang, Y. *et al.* Control of salicylic acid synthesis and systemic acquired resistance by
- 523 two members of a plant-specific family of transcription factors. *Proc. Natl. Acad. Sci.*
- 524 *USA* **107**, 18220–18225 (2010).
- 525 14. Zhu, Z. *et al.* *Arabidopsis* resistance protein SNC1 activates immune responses through
- 526 association with a transcriptional corepressor. *Proc. Natl. Acad. Sci. USA* **107**, 13960–
- 527 13965 (2010).
- 528 15. Kidd, B. N. *et al.* The mediator complex subunit PFT1 is a key regulator of jasmonate-
- 529 dependent defense in *Arabidopsis*. *Plant Cell* **21**, 2237–2252 (2009).
- 530 16. Zhou, C., Zhang, L., Duan, J., Miki, B. & Wu, K. HISTONE DEACETYLASE19 is
- 531 involved in jasmonic acid and ethylene signaling of pathogen response in *Arabidopsis*.
- 532 *Plant Cell* **17**, 1196–1204 (2005).
- 533 17. Walley, J. W. *et al.* The chromatin remodeler SPLAYED regulates specific stress
- 534 signaling pathways. *PLoS Pathog.* **4**, e1000237 (2008).
- 535 18. Tsompana, M. & Buck, M. J. Chromatin accessibility: a window into the genome.
- 536 *Epigenetics Chromatin* **7**, 33 (2014).
- 537 19. Lu, Z., Hofmeister, B. T., Vollmers, C., DuBois, R. M. & Schmitz, R. J. Combining
- 538 ATAC-seq with nuclei sorting for discovery of cis-regulatory regions in plant genomes.
- 539 *Nucleic Acids Res.* **45**, e41 (2017).
- 540 20. Maher, K. A. *et al.* Profiling of Accessible Chromatin Regions across Multiple Plant
- 541 Species and Cell Types Reveals Common Gene Regulatory Principles and New Control
- 542 Modules. *Plant Cell* **30**, 15–36 (2018).
- 543 21. Potter, K. C., Wang, J., Schaller, G. E. & Kieber, J. J. Cytokinin modulates context-
- 544 dependent chromatin accessibility through the type-B response regulators. *Nat. Plants* **4**,
- 545 1102–1111 (2018).

- 546 22. Frerichs, A., Engelhorn, J., Altmüller, J., Gutierrez-Marcos, J. & Werr, W. Specific  
547 chromatin changes mark lateral organ founder cells in the *Arabidopsis thaliana*  
548 inflorescence meristem. *J. Exp. Bot.* (2019). doi:10.1093/jxb/erz181
- 549 23. Lu, Z. *et al.* The prevalence, evolution and chromatin signatures of plant regulatory  
550 elements. *Nat. Plants* **5**, 1250–1259 (2019).
- 551 24. Buenrostro, J. D., Giresi, P. G., Zaba, L. C., Chang, H. Y. & Greenleaf, W. J.  
552 Transposition of native chromatin for fast and sensitive epigenomic profiling of open  
553 chromatin, DNA-binding proteins and nucleosome position. *Nat. Methods* **10**, 1213–  
554 1218 (2013).
- 555 25. Wang, L. *et al.* CBP60g and SARD1 play partially redundant critical roles in salicylic  
556 acid signaling. *Plant J.* **67**, 1029–1041 (2011).
- 557 26. Sun, T. *et al.* ChIP-seq reveals broad roles of SARD1 and CBP60g in regulating plant  
558 immunity. *Nat. Commun.* **6**, 10159 (2015).
- 559 27. Schmid, M. *et al.* A gene expression map of *Arabidopsis thaliana* development. *Nat.*  
560 *Genet.* **37**, 501–506 (2005).
- 561 28. van der Biezen, E. A., Freddie, C. T., Kahn, K., Parker, J. E. & Jones, J. D. G.  
562 *Arabidopsis* RPP4 is a member of the RPP5 multigene family of TIR-NB-LRR genes  
563 and confers downy mildew resistance through multiple signalling components. *Plant J.*  
564 **29**, 439–451 (2002).
- 565 29. Zhang, Y., Goritschnig, S., Dong, X. & Li, X. A gain-of-function mutation in a plant  
566 disease resistance gene leads to constitutive activation of downstream signal transduction  
567 pathways in suppressor of npr1-1, constitutive 1. *Plant Cell* **15**, 2636–2646 (2003).
- 568 30. Staal, J., Kaliff, M., Dewaele, E., Persson, M. & Dixelius, C. RLM3, a TIR domain  
569 encoding gene involved in broad-range immunity of *Arabidopsis* to necrotrophic fungal  
570 pathogens. *Plant J.* **55**, 188–200 (2008).
- 571 31. Asai, S. *et al.* A downy mildew effector evades recognition by polymorphism of  
572 expression and subcellular localization. *Nat. Commun.* **9**, 5192 (2018).
- 573 32. Dong, O. X. *et al.* Individual components of paired typical NLR immune receptors are  
574 regulated by distinct E3 ligases. *Nat. Plants* **4**, 699–710 (2018).
- 575 33. Xia, S. *et al.* Regulation of transcription of nucleotide-binding leucine-rich repeat-  
576 encoding genes SNC1 and RPP4 via H3K4 trimethylation. *Plant Physiol.* **162**, 1694–  
577 1705 (2013).
- 578 34. Saucet, S. B. *et al.* Two linked pairs of *Arabidopsis* TNL resistance genes independently  
579 confer recognition of bacterial effector AvrRps4. *Nat. Commun.* **6**, 6338 (2015).
- 580 35. Thomas, W. J., Thireault, C. A., Kimbrel, J. A. & Chang, J. H. Recombineering and  
581 stable integration of the *Pseudomonas syringae* pv. *syringae* 61 hrp/hrc cluster into the  
582 genome of the soil bacterium *Pseudomonas fluorescens* Pf0-1. *Plant J.* **60**, 919–928  
583 (2009).
- 584 36. Sohn, K. H., Zhang, Y. & Jones, J. D. G. The *Pseudomonas syringae* effector protein,  
585 AvrRPS4, requires in planta processing and the KRVY domain to function. *Plant J.* **57**,  
586 1079–1091 (2009).
- 587 37. Sijacic, P., Bajic, M., McKinney, E. C., Meagher, R. B. & Deal, R. B. Changes in  
588 chromatin accessibility between *Arabidopsis* stem cells and mesophyll cells illuminate  
589 cell type-specific transcription factor networks. *Plant J.* **94**, 215–231 (2018).
- 590 38. Klemm, S. L., Shipony, Z. & Greenleaf, W. J. Chromatin accessibility and the regulatory  
591 epigenome. *Nat. Rev. Genet.* **20**, 207–220 (2019).
- 592 39. Wildermuth, M. C., Dewdney, J., Wu, G. & Ausubel, F. M. Isochorismate synthase is  
593 required to synthesize salicylic acid for plant defence. *Nature* **414**, 562–565 (2001).
- 594 40. Rekhter, D. *et al.* Isochorismate-derived biosynthesis of the plant stress hormone  
595 salicylic acid. *Science* **365**, 498–502 (2019).

- 596 41. Torrens-Spence, M. P. *et al.* PBS3 and EPS1 Complete Salicylic Acid Biosynthesis from  
597 Isochorismate in Arabidopsis. *Mol. Plant* **12**, 1577–1586 (2019).
- 598 42. Ding, P. & Ding, Y. Stories of salicylic acid: A plant defense hormone. *Trends Plant Sci.*  
599 (2020). doi:10.1016/j.tplants.2020.01.004
- 600 43. Návarová, H., Bernsdorff, F., Döring, A.-C. & Zeier, J. Pipecolic acid, an endogenous  
601 mediator of defense amplification and priming, is a critical regulator of inducible plant  
602 immunity. *Plant Cell* **24**, 5123–5141 (2012).
- 603 44. Ding, P. *et al.* Characterization of a pipecolic acid biosynthesis pathway required for  
604 systemic acquired resistance. *Plant Cell* **28**, 2603–2615 (2016).
- 605 45. Hartmann, M. *et al.* Flavin Monooxygenase-Generated N-Hydroxypipecolic Acid Is a  
606 Critical Element of Plant Systemic Immunity. *Cell* **173**, 456–469.e16 (2018).
- 607 46. Chen, Y.-C. *et al.* N-hydroxy-pipecolic acid is a mobile metabolite that induces systemic  
608 disease resistance in Arabidopsis. *Proc. Natl. Acad. Sci. USA* **115**, E4920–E4929 (2018).
- 609 47. Kulkarni, S. R., Vanechoutte, D., Van de Velde, J. & Vandepoele, K. TF2Network:  
610 predicting transcription factor regulators and gene regulatory networks in Arabidopsis  
611 using publicly available binding site information. *Nucleic Acids Res.* **46**, e31 (2018).
- 612 48. Kidokoro, S. *et al.* Different Cold-Signaling Pathways Function in the Responses to  
613 Rapid and Gradual Decreases in Temperature. *Plant Cell* **29**, 760–774 (2017).
- 614 49. Kim, Y. S. *et al.* CAMTA-Mediated Regulation of Salicylic Acid Immunity Pathway  
615 Genes in Arabidopsis Exposed to Low Temperature and Pathogen Infection. *Plant Cell*  
616 **29**, 2465–2477 (2017).
- 617 50. Yuan, P., Du, L. & Poovaiah, B. W. Ca<sup>2+</sup>/Calmodulin-Dependent AtSR1/CAMTA3  
618 Plays Critical Roles in Balancing Plant Growth and Immunity. *Int. J. Mol. Sci.* **19**,  
619 (2018).
- 620 51. Meyer, C. A. & Liu, X. S. Identifying and mitigating bias in next-generation sequencing  
621 methods for chromatin biology. *Nat. Rev. Genet.* **15**, 709–721 (2014).
- 622 52. Ricci, W. A. *et al.* Widespread long-range cis-regulatory elements in the maize genome.  
623 *Nat. Plants* **5**, 1237–1249 (2019).
- 624 53. Garner, C. M., Kim, S. H., Spears, B. J. & Gassmann, W. Express yourself:  
625 Transcriptional regulation of plant innate immunity. *Semin. Cell Dev. Biol.* **56**, 150–162  
626 (2016).
- 627 54. O'Malley, R. C. *et al.* Cistrome and epicistrome features shape the regulatory DNA  
628 landscape. *Cell* **166**, 1598 (2016).
- 629 55. Soufi, A. *et al.* Pioneer transcription factors target partial DNA motifs on nucleosomes to  
630 initiate reprogramming. *Cell* **161**, 555–568 (2015).
- 631 56. Jin, R. *et al.* LEAFY is a pioneer transcription factor and licenses cell reprogramming to  
632 floral fate. *BioRxiv* (2020). doi:10.1101/2020.03.16.994418
- 633 57. Kim, D. *et al.* TopHat2: accurate alignment of transcriptomes in the presence of  
634 insertions, deletions and gene fusions. *Genome Biol.* **14**, R36 (2013).
- 635 58. Zhang, R. *et al.* A high quality Arabidopsis transcriptome for accurate transcript-level  
636 analysis of alternative splicing. *Nucleic Acids Res.* **45**, 5061–5073 (2017).
- 637 59. Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq  
638 quantification. *Nat. Biotechnol.* **34**, 525–527 (2016).
- 639 60. Patro, R., Duggal, G., Love, M. I., Irizarry, R. A. & Kingsford, C. Salmon provides fast  
640 and bias-aware quantification of transcript expression. *Nat. Methods* **14**, 417–419 (2017).
- 641 61. Li, H. *et al.* The Sequence Alignment/Map format and SAMtools. *Bioinformatics* **25**,  
642 2078–2079 (2009).
- 643 62. Robinson, J. T. *et al.* Integrative genomics viewer. *Nat. Biotechnol.* **29**, 24–26 (2011).
- 644 63. Guo, W. *et al.* 3D RNA-seq - a powerful and flexible tool for rapid and accurate  
645 differential expression and alternative splicing analysis of RNA-seq data for biologists.

- 646 *BioRxiv* (2019). doi:10.1101/656686
- 647 64. Risso, D., Ngai, J., Speed, T. P. & Dudoit, S. Normalization of RNA-seq data using  
648 factor analysis of control genes or samples. *Nat. Biotechnol.* **32**, 896–902 (2014).
- 649 65. Robinson, M. D. & Oshlack, A. A scaling normalization method for differential  
650 expression analysis of RNA-seq data. *Genome Biol.* **11**, R25 (2010).
- 651 66. Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing  
652 and microarray studies. *Nucleic Acids Res.* **43**, e47 (2015).
- 653 67. Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: Precision weights unlock linear  
654 model analysis tools for RNA-seq read counts. *Genome Biol.* **15**, R29 (2014).
- 655 68. Buenrostro, J. D., Wu, B., Chang, H. Y. & Greenleaf, W. J. ATAC-seq: A Method for  
656 Assaying Chromatin Accessibility Genome-Wide. *Curr. Protoc. Mol. Biol.* **109**, 21.29.1-  
657 21.29.9 (2015).
- 658 69. Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. *Nat.*  
659 *Methods* **9**, 357–359 (2012).
- 660 70. Zhang, Y. *et al.* Model-based analysis of ChIP-Seq (MACS). *Genome Biol.* **9**, R137  
661 (2008).
- 662 71. Quinlan, A. R. & Hall, I. M. BEDTools: a flexible suite of utilities for comparing  
663 genomic features. *Bioinformatics* **26**, 841–842 (2010).
- 664 72. Yu, G., Wang, L.-G. & He, Q.-Y. ChIPseeker: an R/Bioconductor package for ChIP  
665 peak annotation, comparison and visualization. *Bioinformatics* **31**, 2382–2383 (2015).
- 666 73. Conway, J. R., Lex, A. & Gehlenborg, N. UpSetR: an R package for the visualization of  
667 intersecting sets and their properties. *Bioinformatics* **33**, 2938–2940 (2017).
- 668 74. Raudvere, U. *et al.* g:Profiler: a web server for functional enrichment analysis and  
669 conversions of gene lists (2019 update). *Nucleic Acids Res.* **47**, W191–W198 (2019).
- 670 75. Kulkarni, S. R., Jones, D. M. & Vandepoele, K. Enhanced Maps of Transcription Factor  
671 Binding Sites Improve Regulatory Networks Learned from Accessible Chromatin Data.  
672 *Plant Physiol.* **181**, 412–425 (2019).
- 673 76. Frith, M. C., Li, M. C. & Weng, Z. Cluster-Buster: Finding dense clusters of motifs in  
674 DNA sequences. *Nucleic Acids Res.* **31**, 3666–3668 (2003).
- 675 77. Grant, C. E., Bailey, T. L. & Noble, W. S. FIMO: scanning for occurrences of a given  
676 motif. *Bioinformatics* **27**, 1017–1018 (2011).
- 677

## 678 **Acknowledgements**

679 We thank the Gatsby Foundation (United Kingdom) for funding to the JDGJ laboratory. PD  
680 acknowledges support from the European Union’s Horizon 2020 Research and Innovation Program  
681 under Marie Skłodowska-Curie Actions (grant agreement: 656243) and a Future Leader Fellowship  
682 from the Biotechnology and Biological Sciences Research Council (BBSRC) (grant agreement:  
683 BB/R012172/1). TS, RKS, DM and JDGJ were supported by the Gatsby Foundation funding to the  
684 Sainsbury Laboratory. NMP and KV were supported by a BOF grant from Ghent University (grant  
685 agreement: BOF24Y2019001901). WG and RZ were supported by Scottish Government Rural and  
686 Environment Science and Analytical Services division (RESAS), and RZ also acknowledge the  
687 support from a BBSRC Bioinformatics and Biological Resources Fund (grant agreement:

688 BB/S020160/1). BN was supported by the Norwich Research Park (NRP) Biosciences Doctoral  
689 Training Partnership (DTP) funded by BBSRC (grant agreement: BB/M011216/1). SH and XF were  
690 supported by a BBSRC Responsive Mode grant (grant agreement: BB/S009620/1) and a European  
691 Research Council Starting grant ‘SexMeth’ (grant agreement: 804981).. CL was supported by  
692 Deutsche Forschungsgemeinschaft (grant agreement: LI 2862/4).

693

## 694 **Author contributions**

695 PD and JDGJ conceptualized and designed the research. PD conducted all experiments with  
696 assistance from BPMN and SH. PD together with TS, RKS, NMP, WG and CL performed data  
697 analyses with assistance from DM, RZ and KV. PD wrote the manuscript with input from all co-  
698 authors. All authors helped editing and finalizing the manuscript.

699

## 700 **Competing interests**

701 The authors declare no competing interests.

702

## 703 **Figure legends**

### 704 **Figure 1. Interrogation of chromatin landscapes activated by SRMI and ‘SRMI+IRMI’.**

705 **(a)** Heatmaps showing the distribution of accessible regions around the TSS identified by FANS-  
706 ATAC-seq in two biological replicates (rep) under four different conditions. Accessible regions are  
707 mapped to 2, 000 bp upstream (-2k) or downstream (2k) of TSS as the center. ‘No treatment’, Mock,  
708 SRMI and ‘SRMI+IRMI’ are indicated in black, orange, blue and vermillion, respectively (same color  
709 codes apply to the same set of treatments in the rest of this study). **(b)** Distribution of accessible  
710 regions around the TSS (left panel) and TTS (right panel) identified from FANS-ATAC-seq with the  
711 mean peak counts from two biological replicates indicated in (a). The center of accessible regions was  
712 used to produce the distribution plots. **(c)** An UpSet plot showing the relationships of accessible  
713 regions enriched under four different conditions indicated in (a) and (b). ‘Intersection Size’ indicates  
714 either condition specific accessible regions or shared accessible regions under different combinations

715 of condition comparisons. ‘Set Size’ indicates the aggregates or total number of accessible regions  
716 found under each condition. **(d-f)** Genome browser views of ATAC-seq-indicated chromatin  
717 accessibility changes occurring near selected gene loci under different conditions. Gene symbols are  
718 labeled for the corresponding gene loci, (d) *UBQ10*, (e) *SNCI* and (f) *SARD1*. The protein coding  
719 strand is indicated in black arrow placed next to the gene symbol. The reddish-purple bars next to  
720 each gene loci indicate their putative promoter regions.

721 **Related supplementary information:**

722 Supplementary Fig. 5

723 Supplementary Tables 2 and 3

724

725 **Figure 2. Integration of ATAC-seq with RNA-seq for genes activated by SRMI and**  
726 **‘SRMI+IRMI’**

727 **(a-f)** and **(g-i)** Genome browser views of ATAC-seq and RNA-seq on indicated gene loci under  
728 different conditions. **(a)** and **(g)** are data for *ICS1* locus. **(b)** and **(h)** are data for *EDS5* locus. **(c)** and **(i)**  
729 are data for *PBS3* locus. **(d)** and **(j)** are data for *ALD1* locus. **(e)** and **(k)** are data for *SARD4* locus. **(f)**  
730 and **(l)** are data for *FMO1* locus. *ICS1*, *EDS5* and *PBS3* are genes encoding enzymes that are required  
731 for the biosynthesis of a defense hormone, salicylic acid (SA) in the isochorismate pathway. *ALD1*,  
732 *SARD4* and *FMO1* are enzyme encoding genes involved in the biosynthesis of a secondary metabolite,  
733 N-hydroxy pipelicolic acid (NHP) that are required to initiate systemic acquired resistance in plants.  
734 ATAC-seq data contain the same four conditions as shown in Figure 1, whereas the data point of  
735 Mock treatment is absent in RNA-seq data (NA). ATAC-seq and RNA-seq data points with the same  
736 corresponding labels indicate they were collected under exactly the same conditions (see more details  
737 in Methods).

738 **Related supplementary information:**

739 Supplementary Fig. 6

740 Supplementary Tables 4 and 5

741

742 **Figure 3. Characterization of chromatin accessible regions activated by IRMI**



743 (a) and (b) Genome browser views of chromatin accessible regions on selected gene loci under  
744 different conditions, including IRMI. ‘No treatment\_1’ and ‘No treatment\_2’ are colored in black.  
745 Mock\_1, Mock\_2 and IRMI\_mut are colored in orange. IRMI is colored in bluish green. Same color  
746 codes apply to the same corresponding conditions in the rest of this study. Gene symbols are labeled  
747 for the corresponding gene loci, (a) *ICSI* and (b) *UBQ10*. The protein coding strand is indicated in  
748 black arrow placed next to the gene symbol. The reddish-purple bars next to each gene loci indicate  
749 their putative promoter regions.

750 **Related supplementary information:**

751 Supplementary Fig. 8

752 Supplementary Tables 8

753

754 **Figure 4. Determining chromatin accessibility changes and changes in gene expressions**  
755 **activated by SRMI, IRMI and ‘SRMI+IRMI’**

756 (a) and (b) Genome browser views of differential accessible chromatin regions (ACRs) near genes  
757 that are transcriptionally upregulated in SRMI, IRMI and ‘SRMI+IRMI’ compared to Mock  
758 treatments. (a) Gene loci (*ICSI*, *FMO1* and *RbohD*) with increased ACRs in all indicated conditions.  
759 (b) Gene loci either have no increased ACRs in all conditions (*BIK1*) or only show increased ACRs in  
760 IRMI (*PEPR2* and *SARDI*). Other labels follow same keys indicated in Figure 1 to 3. (c) Integration  
761 of differential accessible regions (DAGs) and differential expression genes (DEGs) between SRMI  
762 and ‘SRMI+IRMI’. There the DAGs indicate the nearest gene loci. The Venn diagrams on the left or  
763 right sides show upregulated DARs (circle with dotted pattern) and DEGs (dashed circle with color  
764 filled) in SRMI (blue, left) or ‘SRMI+IRMI’ (vermillion, right) compared to ‘No treatment’ controls.  
765 Shared gene loci with both DARs and DEGs (intersection area in the Venn diagrams, or ‘DAR  $\cap$   
766 DEG’) from SRMI (n = 1635) and ‘SRMI+IRMI’ (n = 1722) were compared again in the Venn  
767 diagram in the middle. (d) Integration of DAGs and DEGs in IRMI. The Venn diagram (bluish green)  
768 shows upregulated DARs (circle with dotted pattern) and DEGs (dashed circle with color filled) in  
769 IRMI compared to Mock controls. (e) Comparisons of upregulated DEGs in SRMI, IRMI and  
770 ‘SRMI+IRMI’ compared to corresponding negative controls (‘No treatment’ or Mock). (f)

771 Comparisons of upregulated DAGs in SRMI, IRMI and ‘SRMI+IRMI’ compared to corresponding  
772 negative controls (‘No treatment’ or Mock). (g) Comparisons of upregulated ‘DAR  $\cap$  DEG’ in SRMI,  
773 IRMI and ‘SRMI+IRMI’ compared to Controls (‘No treatment’ or Mock).

774 **Related supplementary information:**

775 Supplementary Fig. 7, 8 and 9

776 Supplementary Tables 7, 8 and 9

777

778 **Figure 5. Overview of regulatory TFs across the different gene regulatory networks.**

779 (a) Venn diagram showing shared and unique TFs across the different networks inferred for each  
780 condition. (b) Heatmap with the number of TF family members in each of the Venn diagram sets, as  
781 indicated by the coloring of each cell. TFs that are specific to SRMI, IRMI and ‘SRMI+IRMI’ are  
782 highlighted with corresponding color code. (c) Heatmap displaying presence or absence of GO terms  
783 enrichment in each of the Venn diagram sets. Numbers at the right indicate the number of TFs  
784 showing GO enrichment. TFs that are specific to IRMI are enriched in ‘plant-type hypersensitive  
785 response’ and ‘regulation of cell death’ (in blueish green).

786 **Related supplementary information:**

787 Supplementary Fig. 10 and 11

788 Supplementary Tables 10

789

790 **Figure 6. TF-GO term network for condition-specific TFs**

791 Network diagram with the TFs specific for each condition ‘SMRI’, ‘IRMI’ and ‘SRMI+IRMI’  
792 organized in circles linked to the GO terms enriched in the putative target genes they control. The GO  
793 terms are colored according to whether they are exclusive of any specific condition or if they belong  
794 in any of the possible intersections of the conditions. The GO terms controlled by TFs exclusive of  
795 one condition are in the most outer parts. The GO terms controlled by TFs exclusive of two and three  
796 conditions are located closer to the center and in the center, respectively. Note there are not GO terms  
797 shared between TFs of SRMI and IRMI. Also, there are no GO terms that are exclusive of

798 ‘SRMI+IRMI’ and ‘SRMI  $\cap$  IRMI’ because none of them are controlled by SRMI, IRMI or  
799 ‘SRMI+IRMI’ exclusive TFs.

800 **Related supplementary information:**

801 Supplementary Fig. 12

802 Supplementary Tables 10

803

804 **Supplementary information**

805 **Supplementary Figure 1. Schematic view of integrated plant innate immune system.**

806 Here plant-pathogen interactions are reflected by plant-bacteria interactions. Bacterial plant pathogens  
807 propagate exclusively in the extracellular spaces of plant tissues. Pathogen-Associated Molecular  
808 Patterns (PAMPs) released from the pathogens into the extracellular spaces, such as flagellin and  
809 elongation factor thermo unstable (EF-Tu) are recognized by cell surface Pattern Recognition  
810 Receptors (PRRs) and elicit Pattern-Triggered Immunity (PTI) or here as a refined term cell Surface  
811 Receptor-Mediated Immunity (SRMI). Bacterial pathogens deliver effector proteins into the host cell  
812 by a type-III secretion pilus system (T3SS). These intracellular effectors often act to suppress SRMI.  
813 However, many are recognized by intracellular nucleotide-binding (NB)-LRR receptors (NLRs),  
814 which induces Effector-Triggered Immunity (ETI) or here as a refined term Intracellular Receptor-  
815 Mediated Immunity (IRMI). Both SRMI and IRMI can lead to the transcriptional reprogramming by  
816 recruiting transcription factors (TFs) to the target gene loci, such as their promoters, and activate  
817 defense gene expression for effective bacterial resistance.

818

819 **Supplementary Figure 2. Establishment of FANS-ATAC-seq for Arabidopsis leaf tissue.**

820 (a) A simplified workflow for fluorescence-assisted nuclei sorting (FANS) of leaf nuclei purification.

821 (b) Composition of Tn5 transposasome for DNA tagmentation. (c) Schematic view of assay for  
822 transposase-accessible chromatin followed by sequencing (ATAC-seq).

823

824 **Supplementary Figure 3. Trial run results of FANS-ATAC-seq for Arabidopsis leaf tissue**  
825 **demonstrate a good reproducibility.**

826 (a) Snapshot of FANS-ATAC-seq results on the Integrative Genomics Viewer (IGV) genome browser  
827 from the trial experiment. (b-e) Correlation co-efficiency analysis for different leaf nuclei input in  
828 FANS-ATAC-seq trial experiment. (a), (b), (c) and (d) are analysis between the first biological  
829 replicate (replicate 1 or rep1) and rep 2 for 10,000 (10k), 20k, 50k and 80k nuclei input, respectively.  
830 Adjusted R square ( $R^2$ ) values from all individual comparisons are all greater than 0.9, indicating a  
831 high reproducibility of the FANS-ATAC-seq results from FANS-ATAC-seq workflow established in  
832 this study.

833

834 **Supplementary Figure 4. FANS-ATAC-seq using Arabidopsis leaf nuclei, vegetative and sperm**  
835 **nuclei derived from Arabidopsis pollen grain show tissue-specific chromatin accessibility.**

836 (a) Comparative view of accessible chromatin regions (ACRs) between somatic and germline cells at  
837 *SARD1* gene locus. (b) Comparative view of ACRs between somatic and germline cells at a  
838 *Resistance(R)*-gene NLR gene cluster loci.

839

840 **Supplementary Figure 5. Additional information of FANS-ATAC-seq for chromatin landscapes**  
841 **activated by SRMI and ‘SRMI+IRMI’.**

842 (a) Simplified table for the information of experimental design for RNA-seq. Four conditions include  
843 SRMI, ‘SRMI+IRMI’ with ‘No treatment’ and Mock as control. SRMI is implied by the infiltration of  
844 Pf0-1 EtHAn carrying mutant AvrRps4 (KR VY 135-138 to AAAA) (Pf0-1:AvrRps4<sup>mut</sup>), which  
845 cannot activate NLRs. ‘SRMI+IRMI’ is activated by the infiltration of Pf0-1:AvrRps4<sup>WT</sup> that is  
846 recognized by NLRs RRS1/RPS4 and RRS1B/RPS4B. Mock infiltration with 10 mM MgCl<sub>2</sub> serves as  
847 control for wounding induced during the infiltration process. All sample with infiltration were  
848 collected at 4 hours post infiltration (hpi) and immediately used for FANS-ATAC-seq. (b) Genome  
849 browser views of ATAC-seq-indicated chromatin accessibility genome-wide coverage under different  
850 conditions. (c-f) Accessible chromatin regions from all conditions are mapped to different genomic  
851 features as indicated.

852

853 **Supplementary Figure 6. RNA-seq implies differential gene expression during the activation of**  
854 **SRMI and ‘SRMI+IRMI’.**

855 (a) Simplified table for the information of experimental design for RNA-seq. Three conditions include  
856 SRMI, ‘SRMI+IRMI’ with ‘No treatment’ as control. SRMI is implied by the infiltration of Pf0-1  
857 EtHAn carrying mutant AvrRps4 (KRVY 135-138 to AAAA) (Pf0-1:AvrRps4<sup>mut</sup>), which cannot  
858 activate NLRs. ‘SRMI+IRMI’ is activated by the infiltration of Pf0-1:AvrRps4<sup>WT</sup> that is recognized  
859 by NLRs RRS1/RPS4 and RRS1B/RPS4B. All sample with infiltration were collected at 4 hours post  
860 infiltration (hpi) for RNA extraction and RNA-seq. (b) Volcano plots for differentially expressed  
861 genes (DEGs) in different conditions. The left panel shows SRMI vs ‘No treatment’ and the right  
862 shows ‘SRMI+IRMI’ vs ‘No treatment’. (c) Venn diagram illustration DEG comparison between  
863 SRMI and ‘SRMI+IRMI’. The left Venn diagram shows comparison of upregulated genes between  
864 SRMI and ‘SRMI+IRMI’ and the right shows comparison of downregulated genes. Lists of genes  
865 shown in the Venn diagram can be found in Supplementary Table 4. (a-c) Treatments are color coded  
866 with color-blind friendly palette. ‘No treatment’ in black, SRMI in blue and ‘SRMI+IRMI’ in  
867 vermillion. (d) Heat map of DEGs based on row z-scores comparing three indicated conditions.  
868 Upregulated genes are colored in reddish purple, and downregulated genes are colored in blue. We  
869 only set up to 10 clusters. Quantifications of DEGs and related statistics can be found in  
870 Supplementary Table 5. (e-f) Gene ontology (GO) enrichment for DEGs in SRMI vs ‘No treatment’.  
871 (g-h) GO enrichment for DEGs in ‘SRMI+IRMI’ vs ‘No treatment’. (e-h) Top 5 GO terms were  
872 shown in different enrichment analysis, including ‘biological process (BP)’ in vermillion, ‘molecular  
873 function (MF)’ in bluish green and ‘cellular compartment (CC)’ in blue (same color code for the rest  
874 of the figures in this study). The cut-off for the false discovery rate (FDR) was selected for less than  
875 0.05 (FDR < 0.05) as significant enrichment. The y-axis indicates the value of -log<sub>10</sub>(FDR) for each  
876 GO terms shown. (i-k) GO analysis for DEGs in Cluster 5, 7 and 9 indicated the heat map in (d),  
877 respectively. Numbers of DEGs in Cluster 5, 7 and 9 are 572, 729 and 1704, respectively. Expression  
878 of genes in Cluster 5, 7 and 9 are genes that have higher expression in ‘SRMI+IRMI’ than in SRMI  
879 alone, or IRMI-boosted genes (IBGs). FDR < 0.05.

880

881 **Supplementary Figure 7. RNA-seq implies differential gene expression during the activation of**  
882 **IRMI.**

883 (a) Simplified table for the information of experimental design for RNA-seq. IRMI and four different  
884 control conditions including ‘No treatment’, Control\_1, Control\_2 and IRMI\_mut are shown here.  
885 IRMI is implied by the infiltration of 50  $\mu$ M  $\beta$ -estradiol (E2) in leaves of SETI<sup>WT</sup> (inducible AvrRps4  
886 expressing plants, E2:AvrRps4<sup>WT</sup>). ‘No treatment’ in SETI<sup>WT</sup> serves as a negative control for any  
887 concerns regarding possible leakage of the inducible line. Control\_1 with E2 infiltrated SETI<sup>WT</sup>  
888 harvest at 0 hpi is for the condition before IRMI activation, so serves as a negative control of IRMI  
889 inactive condition. The inducible line SETI<sup>mut</sup> expressing a mutant AvrRps4 (KRKY135-138AAA)  
890 (E2:AvrRps4<sup>mut</sup>) at 4 hpi of the infiltration of 50  $\mu$ M E2 serves as a negative control for the concern  
891 of side effects of E2 might cause to Arabidopsis plants, and also serve as a negative control for the  
892 potential wounding effect introduced by the process of infiltration (IRMI\_mut). All sample with  
893 infiltration were collected at indicated time points in the table for RNA extraction and RNA-seq. (b)  
894 Volcano plots for differentially expressed genes (DEGs) in different conditions. The left panel shows  
895 IRMI vs ‘Control\_1’, which indicates DEGs of before and after IRMI activation. The right panel  
896 shows ‘IRMI’ vs ‘IRMI\_mut’, which indicates the DEGs of IRMI normalized against wounding. Both  
897 contains DEGs that are specific to IRMI. (c) Venn diagram illustration DEG comparison between two  
898 different comparisons in (b). The left Venn diagram shows comparison of upregulated genes and the  
899 right shows comparison of downregulated genes. Lists of genes shown in the Venn diagram can be  
900 found in Supplementary Table 6. (a-c) Treatments are color coded with color-blind friendly palette.  
901 ‘No treatment’ in black. Control\_1, Control\_2 and IRMI\_mut in orange. IRMI in bluish green. (d)  
902 Heat map of DEGs based on row z-scores comparing three indicated conditions. Upregulated genes  
903 are colored in reddish purple, and downregulated genes are colored in blue. We only set up to 10  
904 clusters. Quantifications of DEGs and related statistics can be found in Supplementary Table 7. (e-f)  
905 GO enrichment for DEGs in IRMI vs Control\_1. (g-h) GO enrichment for DEGs in IRMI vs  
906 IRMI\_mut. (e-h) Top 5 GO terms were shown in different enrichment analysis, including BP, MF and  
907 CC. The cut-off for the false discovery rate (FDR) was selected for less than 0.05 (FDR < 0.05) as

908 significant enrichment. The y-axis indicates the value of  $-\log_{10}(\text{FDR})$  for each GO terms shown. **(i-k)**  
909 GO analysis for DEGs in Cluster 7, 8 and 9 indicated the heat map in (d), respectively. Numbers of  
910 DEGs in Cluster 7, 8 and 9 are 1509, 666 and 1282, respectively. Expression of genes in Cluster 7~9  
911 are genes that have higher expression in IRMI than in all the other control conditions, or IRMI-  
912 elevated genes.  $\text{FDR} < 0.05$ .

913

#### 914 **Supplementary Figure 8. Interrogation of chromatin landscapes activated by IRMI.**

915 **(a)** Simplified table for the information of experimental design for FANS-ATAC-seq. IRMI and five  
916 different control conditions including ‘No treatment\_1’, Mock\_1, ‘No treatment\_2’, Mock\_2 and  
917 IRMI\_mut are shown here. IRMI is implied by the infiltration of 50  $\mu\text{M}$   $\beta$ -estradiol (E2) in leaves of  
918 SETI<sup>WT</sup> (inducible AvrRps4 expressing plants, E2:AvrRps4<sup>WT</sup>). ‘No treatment\_1’ in SETI<sup>WT</sup> serves as  
919 a negative control for any concerns regarding possible leakage of the inducible line. Mock\_1 with 0.1%  
920 DMSO infiltrated SETI<sup>WT</sup> harvest at 4 hpi is a control for wounding caused by infiltration, so serves  
921 as a negative control of IRMI inactive condition. The inducible line SETI<sup>mut</sup> expressing a mutant  
922 AvrRps4 (KR<sub>VY</sub>135-138AAAA) (E2:AvrRps4<sup>mut</sup>) at 4 hpi of the infiltration of 50  $\mu\text{M}$  E2 serves as a  
923 negative control for the concern of side effects of E2 might cause to Arabidopsis plants, and also  
924 serve as a negative control for the potential wounding effect introduced by the process of infiltration  
925 (IRMI\_mut). All sample with infiltration were collected at indicated time points in the table and  
926 immediately used for FANS-ATAC-seq. **(b)** Heatmaps showing the distribution of accessible regions  
927 around the TSS identified by FANS-ATAC-seq (average value of two biological replicates) under  
928 four different conditions. Accessible regions are mapped to 2, 000 bp upstream (-2k) or downstream  
929 (2k) of TSS as the center. ‘No treatment\_1’ and ‘No treatment\_2’ are indicated in black; Mock\_1,  
930 Mock\_2 and IRMI\_mut are indicated in orange; IRMI is indicated in blueish green. (same color codes  
931 apply to the same set of treatments in the rest of this study). **(c)** Distribution of accessible regions  
932 around the TSS (left panel) and TTS (right panel) identified from FANS-ATAC-seq with the mean  
933 peak counts from two biological replicates indicated in (b). The center of accessible regions was used  
934 to produce the distribution plots. **(e-j)** Accessible chromatin regions from all conditions are mapped to  
935 different genomic features as indicated.

936

937 **Supplementary Figure 9. Normalization of accessible chromatin regions for DARs and related**  
938 **GO enrichment.**

939 (a-c) Schematic demonstration of normalization of accessible chromatin regions for DARs. (a) SRMI,  
940 (b) IRMI and (c) 'SRMI+IRMI' were normalized to corresponding Mock, respectively. More details  
941 can be found in Methods. (d) GO enrichment for top 5 listed terms for 1413 genes listed in the  
942 intersection of 'DAR  $\cap$  DEG' in SRMI and 'DAR  $\cap$  DEG' in 'SRMI+IRMI' in Fig. 4c. (e) GO  
943 enrichment for top 5 listed terms for 947 genes listed in the intersection of DARs and DEGs in IRMI  
944 in Fig. 4d.

945

946 **Supplementary Figure 10. TF target gene GO enrichment heatmaps.**

947 (a - c) Heatmaps showing the GO enrichment  $-\log_{10}(\text{q-value})$  of the putative target genes for each TF.  
948 (a) SRMI. (b) IRMI, (c) 'SMRI+IRMI'.

949

950 **Supplementary Figure 11. Network centrality parameters.**

951 (a) Number of TFs in each network, the number of putative target genes they control and the  
952 interactions that there are between them for each condition and for set D. Set D is a control network  
953 that contains the DE TFs shared in the three conditions and all the non-redundant target genes and  
954 interactions that each of these TFs have in the three networks. (b) In-degree, out-degree, clustering  
955 coefficient and betweenness centrality computations for all the nodes in each network. The statistical  
956 significance was determined pairwise against the set D network with a two-sided Mann-Whitney U  
957 test (\*\*\*) means  $p\text{-value} < 0.001$ ). The network parameters were computed using NetworkX python  
958 package v2.4.

959

960 **Supplementary Figure 12. IRMI network for targets with high clustering coefficient.**



961 The nodes from the IRMI network that have a clustering coefficient  $\geq 0.5$  and the incoming TFs that  
962 putatively control their expression are represented in the network. The nodes are colored according to  
963 their clustering coefficient.

964

965 **Supplementary Tables**

966 **Supplementary Table 1: Dual index primers for multiplexing; associated with Supplementary**  
967 **Fig. 2 and Fig. 3**

968 **Supplementary Table 2: Distribution of enriched accessible chromatin on different genomic**  
969 **features under different treatments in Supplementary Fig.5**

970 Supplementary Table S2.1: Distribution of enriched accessible chromatin on different genomic  
971 features in 'No treatment'

972 Supplementary Table S2.2: Distribution of enriched accessible chromatin on different genomic  
973 features in Mock

974 Supplementary Table S2.3: Distribution of enriched accessible chromatin on different genomic  
975 features in SRMI

976 Supplementary Table S2.4: Distribution of enriched accessible chromatin on different genomic  
977 features in 'SRMI+IRMI'

978 **Supplementary Table 3: Accessible chromatin regions enriched in different treatment groups**  
979 **and intersections between groups in Fig.1c**

980 **Supplementary Table 4: Statistics of differentially expressed genes listed in Supplementary Fig.**  
981 **6c**

982 Supplementary Table S4.1: Statistics of up-regulated genes in Supplementary Fig. 6c

983 Supplementary Table S4.2: Statistics of down-regulated genes in Supplementary Fig. 6c

984 **Supplementary Table 5: Expression value and cluster information of genes listed in**  
985 **Supplementary Fig. 6d**

986 Supplementary Table S5.1: Transcripts Per Million (TPM) for gene expression profiling related to  
987 Supplementary Fig. 6d

988 Supplementary Table S5.2: Gene targets enriched in each cluster listed in Supplementary Fig. 6d

989 **Supplementary Table 6: Statistics of differentially expressed genes listed in Supplementary Fig.**

990 **7c**

991 **Supplementary Table 7: Expression value and cluster information of genes listed in**

992 **Supplementary Fig. 7d**

993 Supplementary Table S7.1: Transcripts Per Million (TPM) for gene expression profiling related to

994 Supplementary Fig. 7d

995 Supplementary Table S7.2: Gene targets enriched in each cluster listed in Supplementary Fig. 7d

996 **Supplementary Table 8: Distribution of enriched accessible chromatin on different genomic**

997 **features under different treatments in Supplementary Fig. 8**

998 Supplementary Table S8.1: Distribution of enriched accessible chromatin on different genomic

999 features in 'No treatment\_1'

1000 Supplementary Table S8.2: Distribution of enriched accessible chromatin on different genomic

1001 features in Mock\_1

1002 Supplementary Table S8.3: Distribution of enriched accessible chromatin on different genomic

1003 features in IRMI

1004 Supplementary Table S8.4: Distribution of enriched accessible chromatin on different genomic

1005 features in 'No treatment\_2'

1006 Supplementary Table S8.5: Distribution of enriched accessible chromatin on different genomic

1007 features in Mock\_2

1008 Supplementary Table S8.6: Distribution of enriched accessible chromatin on different genomic

1009 features in IRMI\_mut

1010 **Supplementary Table 9: Gene lists and their GO terms enriched in DARs and DEGs data**

1011 **integration; related to Fig. 4 and Supplementary Fig. 9**

1012 Supplementary Table 9.1: DARs and DEGs in different contrast groups and intersections between

1013 groups in Fig. 4

1014 Supplementary Table 9.2: Enriched GO terms associated with 'DAR  $\cap$  DEG' shared by SRMI and


1015 'SRMI+IRMI'


1016 Supplementary Table 9.3: Enriched GO terms associated with 'DAR  $\cap$  DEG' in 'IRMI vs Mock'



1017 **Supplementary Table 10: Information for gene regulatory networks learned from ATAC-seq**  
1018 **and RNA-seq under different immune conditions; related to Fig. 5, 6 and Supplementary Fig.**  
1019 **10-12**








1020 Supplementary Table 10.1: Transcription factors and their targets inferred from ATAC-seq and  
1021 transcription factor binding motif information


1022 Supplementary Table 10.2: Gene regulatory network matrix linking transcription factors to their  
1023 targets





















a




b




d



c














**a**


Treatment	Strains	Time point
No treatment	NA	NA
Mock	10 mM MgCl <sub>2</sub>	4 hpi
SRMI	Pf0-1:AvrRps4 <sup>mut</sup>	4 hpi
SRMI+IRMI	Pf0-1:AvrRps4 <sup>WT</sup>	4 hpi














a




b




c



d



e









a

	TF	Targets	Interactions
<b>SMRI</b>	115	1068	23123
<b>IRMI</b>	34	646	6067
<b>SRMI+IRMI</b>	133	1158	27260
<b>Set D</b>	147	760	19328

b

